Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

Treatment of HCV genotype (GT) 2‐infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12‐536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2%...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnell, Gretja, Tripathi, Rakesh, Krishnan, Preethi, Beyer, Jill, Reisch, Thomas, Irvin, Michelle, Dekhtyar, Tatyana, Setze, Carolyn, Rodrigues‐Jr, Lino, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Chayama, Kazuaki, Kumada, Hiromitsu, Collins, Christine, Pilot‐Matias, Tami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680211/
https://www.ncbi.nlm.nih.gov/pubmed/28842997
http://dx.doi.org/10.1002/jmv.24923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680211/
https://www.ncbi.nlm.nih.gov/pubmed/28842997
http://dx.doi.org/10.1002/jmv.24923

Ejemplares similares